https://www.entyviohcp.com/mechanism-of-action See how the only gut-focused biologic for Crohn's and UC works to address inflammation ENTYVIO specifically binds to the α4β7 integrin and blocks its interaction with MAdCAM-1, which is mainly expressed on gut endothelial cells https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/ffb34ef9-e813-47c5-aa66-5d60d8cd4eb5/33497972-b5ac-45e2-9126-d46fa364db4e/1280x720/match/image.jpg https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6361236708112 429 https://www.entyviohcp.com/ulcerative-colitis-efficacy Review the breakthrough trial Head-to-head Varsity trial between Entyvio (vedolizumab) and Humira (adalimumab) https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/fc7e5003-0590-413b-a56b-0a0e07898d5a/dc0b1e11-1795-4d0f-ae0b-57671227b4d3/1280x720/match/image.jpg https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6361237376112 490 https://www.entyviohcp.com/dosing-administration/iv Watch the ENTYVIO IV dosing and administration video Instruction video to administer Entyvio (vedolizumab) intravenous https://cf-images.us-east-1.prod.boltdns.net/v1/jit/2574028764001/c7d12716-8fbd-40e8-820a-bb73ba39d0a7/main/1280x720/5m7s477ms/match/image.jpg https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6361237074112 614 https://www.entyviohcp.com/dosing-administration/pen Watch the ENTYVIO Pen dosing and administration video Instruction video to administer Entyvio (vedolizumab) pen https://cf-images.us-east-1.prod.boltdns.net/v1/jit/2574028764001/ff31371a-f814-4f2b-a2d4-dcc8fa5033d2/main/1280x720/5m48s352ms/match/image.jpg https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6361237980112 696 https://www.entyviohcp.com/peer-perspectives GI Perspective Video Aja McCutchen, MD Dr. Aja McCutchen discusses VARSITY, the first head-to-head study of biologics in UC with ENTYVIO (vedolizumab) vs Humira (adalimumab) and the impact the data has made on her treatment considerations for adult patients with moderately to severely active ulcerative colitis. https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/daf3e083-ab4d-43cd-b1f0-c61d6e67b756/c022a13a-1f4c-471e-b710-6b916f236658/1280x720/match/image.jpg https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6382698682112 814 GI Perspective Video Timothy Ritter, MD and Brooke Hodnick, PA-C, MPAS Dr. Timothy Ritter and his PA Ms. Brooke Hodnick discuss early intervention following the loss of response to conventional therapy, steroids, or TNF blockers for patients with moderately to severely active Crohn's disease. https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/5ad6e050-a22f-45eb-a421-01c7e6662ce0/71f65b5b-6e31-40ac-8e51-70903540e466/1280x720/match/image.jpg https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6361237177112 702 GI Perspective Video - Bincy Abraham, MD, MS Dr. Bincy Abraham discusses how she considers patient preferences and clinical data when choosing ENTYVIO as an option for adults with moderately to severely active ulcerative colitis or Crohn’s disease. https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/d082248e-74d7-47d9-8b7c-cff988fd550b/eadbc512-e10e-466c-9a81-3a57ebb6d259/1280x720/match/image.jpg https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6361237377112 696